Coordination of retrotransposons and type I interferon with distinct interferon pathways in dermatomyositis, systemic lupus erythematosus and autoimmune blistering disease.
Adaptive Immunity
Adult
Aged
Autoimmune Diseases
/ genetics
Cell Line
DNA Methylation
Dermatomyositis
/ genetics
Female
Gene Expression Profiling
Gene Expression Regulation
Humans
Interferon Type I
/ genetics
Long Interspersed Nucleotide Elements
Lupus Erythematosus, Systemic
/ genetics
Male
Middle Aged
Polymerase Chain Reaction
Promoter Regions, Genetic
RNA, Messenger
/ metabolism
Retroelements
Rheumatic Diseases
/ metabolism
Signal Transduction
Journal
Scientific reports
ISSN: 2045-2322
Titre abrégé: Sci Rep
Pays: England
ID NLM: 101563288
Informations de publication
Date de publication:
30 11 2021
30 11 2021
Historique:
received:
20
04
2021
accepted:
18
11
2021
entrez:
1
12
2021
pubmed:
2
12
2021
medline:
27
1
2022
Statut:
epublish
Résumé
Type I interferon (IFN) plays a crucial role in innate and adaptive immunity, and aberrant IFN responses are involved in systemic autoimmune diseases, such as systemic lupus erythematosus (SLE) and dermatomyositis (DM). Type I IFNs can be induced by transcribed retrotransposons. The regulation of retrotransposons and type I IFN and the downstream IFN pathways in SLE, DM, and autoimmune blistering disease (AIBD) were investigated. The gene expression levels of retrotransposons, including LINE-1, type I-III IFNs, and IFN-stimulated genes (ISGs) in peripheral blood cells from patients with DM (n = 24), SLE (n = 19), AIBD (n = 14) and healthy controls (HCs, n = 10) were assessed by quantitative polymerase chain reaction. Upregulation of retrotransposons and IFNs was detected in DM patient samples, as is characteristic, compared to HCs; however, ISGs were not uniformly upregulated. In contrast, retrotransposons and IFNs, except for type II IFN, such as IFN-γ, were not upregulated in SLE. In AIBD, only some retrotransposons and type I interferons were upregulated. The DM, SLE, and AIBD samples showed coordinated expression of retrotransposons and type I IFNs and distinct spectra of IFN signaling. A positive correlation between LINE-1 and IFN-β1 was also detected in human cell lines. These factors may participate in the development of these autoimmune diseases.
Identifiants
pubmed: 34848794
doi: 10.1038/s41598-021-02522-6
pii: 10.1038/s41598-021-02522-6
pmc: PMC8632942
doi:
Substances chimiques
Interferon Type I
0
RNA, Messenger
0
Retroelements
0
Types de publication
Journal Article
Research Support, Non-U.S. Gov't
Langues
eng
Sous-ensembles de citation
IM
Pagination
23146Informations de copyright
© 2021. The Author(s).
Références
Ann Rheum Dis. 2016 Nov;75(11):2014-2021
pubmed: 27088255
Genes Cells. 2016 Jan;21(1):25-40
pubmed: 26592235
Ann Rheum Dis. 2011 May;70(5):831-6
pubmed: 21177291
Arthritis Rheumatol. 2020 Jan;72(1):89-99
pubmed: 31342656
Rheumatology (Oxford). 2019 Jun 1;58(6):1011-1015
pubmed: 30608616
Sci Signal. 2017 Apr 25;10(476):
pubmed: 28442624
Nature. 2006 May 4;441(7089):101-5
pubmed: 16625202
Proc Natl Acad Sci U S A. 1967 Sep;58(3):1004-10
pubmed: 5233831
Nat Immunol. 2017 Jun 20;18(7):716-724
pubmed: 28632714
J Autoimmun. 2017 Mar;78:70-78
pubmed: 28162788
J Clin Invest. 2019 Mar 1;129(3):958-961
pubmed: 30776023
Clin Ter. 2019 Jan-Feb;170(1):e71-e76
pubmed: 30789201
Immunol Rev. 2005 Apr;204:9-26
pubmed: 15790347
Immunol Rev. 2004 Dec;202:8-32
pubmed: 15546383
Genome Res. 2011 Jun;21(6):813-20
pubmed: 21632748
J Biol Chem. 2007 Jul 13;282(28):20059-63
pubmed: 17502367
Proc Natl Acad Sci U S A. 2009 Jun 9;106(23):9373-8
pubmed: 19478064
Curr Opin Rheumatol. 2016 Nov;28(6):636-44
pubmed: 27533321
Arthritis Rheumatol. 2021 May;73(5):858-865
pubmed: 33258553
Cell. 1999 Oct 29;99(3):247-57
pubmed: 10555141
Science. 1999 Jun 11;284(5421):1835-7
pubmed: 10364556
Annu Rev Immunol. 2005;23:307-36
pubmed: 15771573
Arthritis Rheumatol. 2014 Jul;66(7):1888-99
pubmed: 24578190
Arthritis Rheumatol. 2016 Nov;68(11):2686-2696
pubmed: 27338297
Front Immunol. 2018 May 28;9:1135
pubmed: 29892288
N Engl J Med. 2020 Jan 16;382(3):211-221
pubmed: 31851795
Curr Opin Immunol. 2020 Dec;67:87-94
pubmed: 33246136
EMBO Rep. 2018 Oct;19(10):
pubmed: 30061100
Science. 1994 Jun 3;264(5164):1415-21
pubmed: 8197455
J Autoimmun. 2018 Jun;90:105-115
pubmed: 29525183
J Leukoc Biol. 2004 Feb;75(2):163-89
pubmed: 14525967
Nat Commun. 2019 Jul 2;10(1):2921
pubmed: 31266943
Arthritis Rheum. 2009 May;60(5):1463-71
pubmed: 19404947
Immunol Cell Biol. 2012 Sep;90(8):774-83
pubmed: 22249201
Clin Exp Immunol. 2009 Apr;156(1):134-40
pubmed: 19175619
Annu Rev Med. 2015;66:311-28
pubmed: 25587654
J Am Acad Dermatol. 2021 Apr;84(4):1103-1105
pubmed: 32439465
J Biol Chem. 2015 Apr 17;290(16):10191-9
pubmed: 25716322
Autoimmun Rev. 2014 Apr-May;13(4-5):477-81
pubmed: 24424192
J Invest Dermatol. 2015 May;135(5):1253-1260
pubmed: 25615553
Ann Intern Med. 2020 Jun 2;172(11):ITC81-ITC96
pubmed: 32479157
Clin Rev Allergy Immunol. 2017 Apr;52(2):164-181
pubmed: 27216430
Oncogene. 2002 Aug 15;21(36):5593-600
pubmed: 12165858
Arthritis Rheumatol. 2014 Jun;66(6):1583-95
pubmed: 24644022
Front Immunol. 2018 Mar 26;9:541
pubmed: 29632529
Autoimmun Rev. 2014 Apr-May;13(4-5):482-9
pubmed: 24434358
Br J Dermatol. 2010 Jan;162(1):91-101
pubmed: 19785596
Gene. 1997 Apr 21;189(2):227-34
pubmed: 9168132
J Dermatol Sci. 2020 Sep;99(3):213-215
pubmed: 32798124
Annu Rev Immunol. 2014;32:513-45
pubmed: 24555472
Oncogene. 2010 Oct 28;29(43):5775-84
pubmed: 20562909